Calandra T, Gerain J, Heumann D, Baumgartner J D, Glauser M P
Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Am J Med. 1991 Jul;91(1):23-9. doi: 10.1016/0002-9343(91)90069-a.
We measured the serum concentrations of interleukin-6 (IL-6) in 70 patients with established septic shock caused predominantly by gram-negative bacteria. The aims of the study were to determine whether and for how long IL-6 was detectable in the circulation of these patients, to assess whether IL-6 levels were associated with patients' outcomes, and, finally, to examine the interplay between IL-6, tumor necrosis factor (TNF), interleukin-1 beta (IL-1 beta), and interferon-gamma (IFN-gamma).
IL-6 was detected in 64% of the patients at study entry but in only 18% on Day 1 and 2% on Day 10. Serum levels of IL-6 were higher (median: 3.5 ng/mL, range: less than 0.1 to 305 ng/mL) in patients dying of fulminant septic shock than in those surviving (median: 0.5 ng/mL, range: less than 0.1 to 135 ng/mL; p = 0.003) or in those with a transient reversal of shock but who ultimately died of a relapse of shock (median: less than 0.1 ng/mL, range: less than 0.1 to 12.5 ng/mL; p = 0.005). However, no cutoff values of IL-6 confidently predicted the outcome of an individual patient. The serum concentrations of IL-6 measured at study entry correlated with the duration of survival (r = -0.51, p = 0.004) and with the levels of TNF-alpha (r = 0.53; p less than 0.0001) but not with the levels of either IL-1 beta (r = 0.01, p = 0.90) or IFN-gamma (r = 0.06, p = 0.60).
These results indicate that circulating levels of IL-6 are detectable in a majority of patients with gram-negative septic shock. Concentrations of IL-6 peaked near the onset of shock and rapidly decreased to undetectable levels within approximately 24 hours in most patients. Levels of IL-6 measured at study entry correlated with levels of TNF and with patients' outcomes. Yet, IL-6 does not appear to be a clinically useful laboratory test for predicting the outcome of an individual patient.
我们检测了70例主要由革兰氏阴性菌引起的确诊感染性休克患者的血清白细胞介素-6(IL-6)浓度。本研究的目的是确定这些患者循环中是否能检测到IL-6以及能检测到多久,评估IL-6水平是否与患者的预后相关,最后研究IL-6、肿瘤坏死因子(TNF)、白细胞介素-1β(IL-1β)和干扰素-γ(IFN-γ)之间的相互作用。
研究开始时,64%的患者检测到IL-6,但第1天仅18%,第10天仅2%。暴发性感染性休克死亡患者的血清IL-6水平(中位数:3.5 ng/mL,范围:小于0.1至305 ng/mL)高于存活患者(中位数:0.5 ng/mL,范围:小于0.1至135 ng/mL;p = 0.003)或休克短暂逆转但最终死于休克复发的患者(中位数:小于0.1 ng/mL,范围:小于0.1至12.5 ng/mL;p = 0.005)。然而,没有IL-6的临界值能够可靠地预测个体患者的预后。研究开始时测量的IL-6血清浓度与生存时间(r = -0.51,p = 0.004)和TNF-α水平(r = 0.53;p < 0.0001)相关,但与IL-1β水平(r = 0.01,p = 0.90)或IFN-γ水平(r = 0.06,p = 0.60)均无关。
这些结果表明,大多数革兰氏阴性菌感染性休克患者的循环中可检测到IL-6水平。IL-6浓度在休克发作时达到峰值,大多数患者在约24小时内迅速降至检测不到的水平。研究开始时测量的IL-6水平与TNF水平及患者预后相关。然而,IL-6似乎并不是预测个体患者预后的临床有用实验室检测指标。